Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02951195 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

A Phase 2 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
16
Study locations

NCT02951195: Completed Phase 2 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.

NCT02951195 is a Phase 2 study of Cystic Fibrosis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 80 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (55% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02951195, a Phase 2 study of Cystic Fibrosis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

Conditions Studied

Cystic Fibrosis

Interventions

  • DRUG Placebo
  • DRUG IVA
  • DRUG TEZ/IVA
  • DRUG VX-152

Study Locations (16)

California

  • - La Jolla
  • - Los Angeles

Illinois

  • - Chicago
  • - Peoria

Ohio

  • - Akron
  • - Cleveland

Texas

  • - Fort Worth
  • - Houston

Alabama

  • - Birmingham

Florida

  • - Orlando

Missouri

  • - St Louis

North Carolina

  • - Chapel Hill

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2016-11
Est. Completion 2018-01
Phase Phase 2
Vertex Pharmaceuticals Incorporated

191 total trials

What the finished NCT02951195 record still lists

NCT02951195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (55% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02951195 lists 16 locations in 12 states (California, Illinois, Ohio).

Frequently Asked Questions

What is clinical trial NCT02951195 about?

NCT02951195 is a clinical study titled "A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis". This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are ...

What is the current status of trial NCT02951195?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-11. Estimated completion is 2018-01.

What conditions does trial NCT02951195 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT02951195?

The interventions under investigation include: Placebo (DRUG), IVA (DRUG), TEZ/IVA (DRUG), VX-152 (DRUG).

Who is sponsoring clinical trial NCT02951195?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02951195 being conducted?

This trial has 16 study locations across Alabama, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02951195's enrollment target sits among peer trials

80 71st of 169 higher than 98 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02951195, the US trial registry maintained by the National Library of Medicine. NCT02951195 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.